title: [Suitability of strontium ranelate in a health care management area after drug surveillance alerts].
abstract: OBJECTIVE
  To analyse the impact of a strategy on the suitability of strontium ranelate, and its level of acceptance, after issuing recommendations based on drug surveillance alerts issued by the Spanish Medicines and Medical Devices Agency.
  
  
  METHODS
  A prospective interventional study conducted from April 2012 to November 2014.
  
  
  METHODS
  South Seville Health Management Area.
  
  
  METHODS
  Patients currently prescribed with strontium ranelate.
  
  
  METHODS
  The study consisted of four phases linked to the issue of drug surveillance alerts on strontium ranelate by the Spanish Medicines and Medical Devices Agency, listed by patients and suitability recommendations.
  
  
  METHODS
  Suitability of strontium ranelate treatment and the level of acceptance by physicians.
  
  
  RESULTS
  There was a reduction of 87.9% in prescriptions from the beginning of the study, with 182 patients included, until the review of the suitability of the drug began. The prescribing of strontium ranelate was unsuitable in 16 out of the 22 patients remaining; 11 of which were due not meeting the treatment criteria, 3 for not having had previous treatments with other drugs for the prevention of fractures, and 2 due to contraindications. The level of acceptance of the recommendations was 87.5%, leading to the stopping of strontium ranelate in 10 patients, and the changing to alendronate or alendronate/cholecalciferol in another four patients.
  
  
  CONCLUSIONS
  The number of patients prescribed strontium ranelate has decreased considerably. The interventions directed at reviewing the suitability of this treatment, based on the drug surveillance alerts, have been effective.
authors.affiliation: Unidad de Gestión Clínica de Farmacia, Área de Gestión Sanitaria Sur de Sevilla, Sevilla, España. Electronic address: rosa_cantudo@hotmail.com.
authors.forename: M R
authors.initials: MR
authors.lastname: Cantudo-Cuenca
authors.affiliation: Unidad de Gestión Clínica de Farmacia, Área de Gestión Sanitaria Sur de Sevilla, Sevilla, España.
authors.forename: E
authors.initials: E
authors.lastname: Calvo-Cidoncha
authors.affiliation: Unidad de Gestión Clínica de Farmacia, Área de Gestión Sanitaria Sur de Sevilla, Sevilla, España.
authors.forename: M A
authors.initials: MA
authors.lastname: Robustillo-Cortés
authors.affiliation: Unidad de Gestión Clínica de Farmacia, Área de Gestión Sanitaria Sur de Sevilla, Sevilla, España.
authors.forename: M C
authors.initials: MC
authors.lastname: Saborido-Cansino
authors.affiliation: Unidad de Gestión Clínica San Francisco, Área de Gestión Sanitaria Sur de Sevilla, Sevilla, España.
authors.forename: G
authors.initials: G
authors.lastname: Gómez-Estrella
authors.affiliation: Unidad de Gestión Clínica de Farmacia, Área de Gestión Sanitaria Sur de Sevilla, Sevilla, España.
authors.forename: A
authors.initials: A
authors.lastname: Sánchez-Pedrosa
mesh_terms: D050071:Bone Density Conservation Agents / Q000627:therapeutic use*; D050723:Fractures, Bone / Q000517:prevention & control*; D006801:Humans; D057970:Inappropriate Prescribing; D009942:Organometallic Compounds / Q000627:therapeutic use; D010818:Practice Patterns, Physicians'; D011446:Prospective Studies; D013030:Spain; D013876:Thiophenes / Q000627:therapeutic use*
chemical_list: D050071:Bone Density Conservation Agents; D009942:Organometallic Compounds; D013876:Thiophenes; C081587:strontium ranelate
keywords: Adecuación; Adequacy; Alert; Alerta; Ranelato de estroncio; Stromtium ranelate